Atara Biotherapeutics Company Insiders

ATRA Stock  USD 11.47  0.86  8.11%   
Atara Biotherapeutics' insiders are aggressively selling. The analysis of the overall insider sentiment regarding Atara Biotherapeutics suggests that vertually all insiders are panicking. Atara Biotherapeutics employs about 165 people. The company is managed by 15 executives with a total tenure of roughly 7 years, averaging almost 0.0 years of service per executive, having 11.0 employees per reported executive.
Joseph Newell  President
Executive Vice President Chief Technical Operations Officer

Atara Biotherapeutics' Insider Buying Vs Selling

0

 
Selling
 
Buying

Latest Trades

2024-11-18Jill HenrichDisposed 1000 @ 11.2View
2024-08-16Pascal TouchonDisposed 3038 @ 6.63View
2024-05-16Pascal TouchonDisposed 3260 @ 15.5View
2024-03-04Pascal TouchonDisposed 993 @ 18View
Monitoring Atara Biotherapeutics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Atara Biotherapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For information on how to trade Atara Stock refer to our How to Trade Atara Stock guide.

Atara Biotherapeutics' Workforce Through the Years

Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Atara Biotherapeutics' future performance. Based on our forecasts, it is anticipated that Atara will maintain a workforce of about 170 employees by December 2024.
 
Yuan Drop
 
Covid

Atara Biotherapeutics Management Team Effectiveness

The company has return on total asset (ROA) of (0.5748) % which means that it has lost $0.5748 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (20.1486) %, meaning that it created substantial loss on money invested by shareholders. Atara Biotherapeutics' management efficiency ratios could be used to measure how well Atara Biotherapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Equity is expected to grow to 2.92, whereas Return On Tangible Assets are forecasted to decline to (1.75). At present, Atara Biotherapeutics' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 5.1 M, whereas Non Current Assets Total are forecasted to decline to about 44.3 M.
As of November 22, 2024, Common Stock Shares Outstanding is expected to decline to about 4 M. In addition to that, Net Loss is expected to decline to about (215.7 M)

Atara Biotherapeutics Workforce Comparison

Atara Biotherapeutics is rated second in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 700. Atara Biotherapeutics totals roughly 165 in number of employees claiming about 24% of equities under Health Care industry.
The company has Profit Margin (PM) of (2.9) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.62) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.62.

Atara Biotherapeutics Insider Trading History

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Atara Biotherapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Atara Biotherapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Atara Biotherapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Yuan Drop
 
Covid
Buy/Sell Ratio# Purchases Trades# Sales TradesTotal Shares PurchasedTotal Shares Sold
2024-09-01
0.0588
1
17
 45,000 
 183,998 
2024-03-01
1.6667
10
6
 4,105,000 
 56,192 
2023-12-01
0.6667
4
6
 816,825 
 65,084 
2023-06-01
0.5385
14
26
 955,500 
 1,350,001 
2023-03-01
1.1429
8
7
 2,473,619 
 76,180 
2022-06-01
1.875
15
8
 406,500 
 46,664 
2022-03-01
1.0833
13
12
 1,379,714 
 74,885 
2021-12-01
0.2308
3
13
 13,500 
 63,566 
2021-09-01
0.2
2
10
 65,500 
 46,076 
2021-06-01
1.9
19
10
 262,354 
 50,177 
2021-03-01
1.0769
14
13
 837,162 
 39,059 
2020-12-01
0.1538
2
13
 7,000 
 32,833 
2020-06-01
3.0
18
6
 814,750 
 22,942 
2020-03-01
1.8
9
5
 842,625 
 20,365 
2019-06-01
0.8947
17
19
 472,074 
 43,894 
2019-03-01
0.4423
23
52
 413,001 
 344,043 
2018-12-01
0.0833
3
36
 4,500 
 87,949 
2018-09-01
0.1282
5
39
 31,500 
 271,043 
2018-06-01
0.5682
25
44
 460,221 
 187,864 
2018-03-01
0.243
26
107
 688,820 
 566,313 
2017-12-01
0.2857
8
28
 29,760 
 125,038 
2017-09-01
0.2759
8
29
 29,759 
 90,332 
2017-06-01
0.8621
25
29
 423,606 
 105,541 
2017-03-01
0.6829
28
41
 495,178 
 233,061 
2016-12-01
0.2941
10
34
 42,181 
 122,830 
2016-09-01
0.5385
14
26
 582,179 
 427,838 
2016-06-01
0.3704
10
27
 42,181 
 104,145 
2016-03-01
1.2105
23
19
 511,069 
 65,133 
2015-12-01
0.413
19
46
 615,773 
 84,216 
2015-09-01
0.2535
18
71
 287,399 
 551,076 
2015-06-01
0.3043
14
46
 460,182 
 1,290,922 
2014-12-01
1.3913
32
23
 9,868,548 
 4,777,273 

Atara Biotherapeutics Notable Stakeholders

An Atara Biotherapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Atara Biotherapeutics often face trade-offs trying to please all of them. Atara Biotherapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Atara Biotherapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Pascal DVMCEO PresidentProfile
Joseph NewellExecutive Vice President Chief Technical Operations OfficerProfile
Rajani MDSenior OfficerProfile
Eric HyllengrenExecutive OfficerProfile
Jakob MDEx RDProfile
Kerry DalyHead CommunicationsProfile
Jill HenrichExecutive QualityProfile
Utpal MBAEx CFOProfile
Alex ChapmanVice RelationsProfile
Anhco NguyenExecutive OfficerProfile
Manher MDExecutive OfficerProfile
Amie KrauseChief OfficerProfile
Charlene BanardChief OfficerProfile
Amar MuruganExecutive OfficerProfile
Dan MaziaszExecutive OfficerProfile

About Atara Biotherapeutics Management Performance

The success or failure of an entity such as Atara Biotherapeutics often depends on how effective the management is. Atara Biotherapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Atara management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Atara management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets(1.67)(1.75)
Return On Capital Employed(11.86)(11.26)
Return On Assets(1.67)(1.75)
Return On Equity 2.78  2.92 
Please note, the presentation of Atara Biotherapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Atara Biotherapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Atara Biotherapeutics' management manipulating its earnings.

Atara Biotherapeutics Workforce Analysis

Traditionally, organizations such as Atara Biotherapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Atara Biotherapeutics within its industry.

Atara Biotherapeutics Manpower Efficiency

Return on Atara Biotherapeutics Manpower

Revenue Per Employee52K
Revenue Per Executive571.5K
Net Loss Per Employee1.7M
Net Loss Per Executive18.4M

Complementary Tools for Atara Stock analysis

When running Atara Biotherapeutics' price analysis, check to measure Atara Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Atara Biotherapeutics is operating at the current time. Most of Atara Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Atara Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Atara Biotherapeutics' price. Additionally, you may evaluate how the addition of Atara Biotherapeutics to your portfolios can decrease your overall portfolio volatility.
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets